Objective To test the hypothesis that patient-initiated follow up reduces the fear of cancer recurrence (FCR) and healthcare use when compared with traditional hospital-based follow up.
Population One hundred and fifty-six women diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage I low-intermediate risk endometrial carcinoma.
Methods Women allocated to the control group attended hospital-based follow up consisting of regular outpatient visits for 3 years after primary treatment. Women in the intervention group were instructed in patient-initiated follow up, which included careful instruction in alarm symptoms and options for self-referral rather than a schedule of examinations.
Main outcome measures The primary end point was FCR as measured by the Fear of Cancer Recurrence Inventory (FCRI) after 10 months of follow up. Secondary end points included cancer-related use of primary and secondary health care during the first 10 months after treatment.
Results In the primary analysis, FCR decreased significantly more in the control group from baseline to 10 months of follow up (difference À5.9, 95% CI À10.9 to À0.9). The majority of this improvement happened after only 3 months of follow up. Women receiving the intervention had fewer examinations at the department compared with the control group (0 versus 2 median visits, P < 0.01) and 58% of these examinations were scheduled because of vaginal bleeding.
Introduction
The need for routine, hospital-based follow up of earlystage endometrial cancer has been questioned, because little is known of its possible benefits and harms. 1 In general, cancer survivors consider early detection of recurrence to be the primary purpose of post-treatment surveillance 2 and associate follow up with reassurance. 3 However, an upcoming examination can cause distress 2, 4 and may remind the women of their cancer diagnosis, cause them to question their health status, and induce fear of cancer recurrence (FCR). 4 FCR is common among cancer survivors 5, 6 and can be considered a rational response to the threat of recurrence; however, it is associated with psychological distress, impaired functioning, lower quality of life, and increased use of health care. 7 Hence, it is essential to balance post-treatment surveillance with the women's desire to return to normal life.
Current knowledge on the effect of follow up on survival and recurrence detection relies on retrospective studies. 1 The majority of studies conclude that follow up does not improve survival. 1 In a nationwide population-based cohort study, we found that recurrence was symptomatic in the majority of the included women (65.5%) and so could be detected outside regular follow up. 8 Of the recurrences, 53% were extra-vaginal with poor options for treatment, 8 and early detection would most likely not improve survival.
Women with International Federation of Gynecology and Obstetrics (FIGO) stage I low-to intermediate-risk disease have a recurrence risk of 1-3%. 1 Hence, the majority of these women would never experience recurrence and it is estimated that only two in 1000 would potentially benefit from follow up. 1 In addition, routine follow up could delay recurrence diagnosis, because patients postpone seeking help until the next scheduled visit. 8, 9 Consequently, follow-up care is subject to a paradigm shift, in which alternative strategies, including follow up by general practitioners (GP), specialist nurses or the patients themselves is considered. 10 In patient-initiated follow up, patients are instructed in self-referral, based on knowledge of alarm symptoms. They are given direct access to secondary health care, rather than receiving a schedule of examinations. 11 Hence, the approach is expected to reduce the number of unnecessary visits and diagnostic delay caused by patients not reacting to their symptoms. 11 Here, we present the first multicentre randomised trial on patient-initiated follow up in endometrial cancer. The objective of the trial was to compare traditional follow up with patient-initiated follow up regarding FCR and healthcare use in early-stage, low-to intermediate-risk endometrial cancer. We hypothesised that patient-initiated follow up would reduce FCR and reduce cancer-related healthcare use.
Methods

Study design
The study design was a pragmatic, multicentre, parallelgroup randomised superiority trial. 
Participants
Women eligible for participation were treated with curative intent for FIGO stage I, grades 1 and 2 endometrial carcinoma. Exclusion criteria were treatment with adjuvant chemotherapy or radiation therapy, participation in a project with follow-up examinations or follow up for other gynaecological malignancy, tumours with high-risk histology (clear cell, serous, squamous, non-differentiated adenocarcinoma), and inability to complete questionnaires, because of mental impairment or insufficient literacy in Danish.
Written study information was administered at the department of gynaecology before initial surgery and was repeated verbally by a specialist in gynaecological cancer surgery before discharge. This information included a description of the study design, implications for participants, a description of the most important alarm symptom (vaginal bleeding/discharge) and contact information for the department of gynaecology. Participants gave informed written consent.
Randomisation and masking
The women were randomly assigned (1 : 1) to hospitalbased or patient-initiated follow-up care at the time of final FIGO staging following surgery, using a computer-based system stratified according to healthcare centre. Randomisation was performed centrally with a block size of ten within each hospital. Healthcare providers and data analysts were blinded to the block size during recruitment. Neither patients nor healthcare providers could be blinded to the enrolment. However, data analysts were blinded to the group assignment until all the analyses were completed, by labelling the groups with non-identifying terms (1 and 2).
Procedures
The intervention consisted of patient-initiated follow up without a schedule of examinations at the respective department of gynaecology. The women were thoroughly instructed in alarm symptoms that required examination, that is vaginal bleeding/discharge or other newly emerged symptoms including: pelvic pain/heaviness, distended abdomen, dyspnoea, gastrointestinal symptoms, fatigue, weight loss and swelling of the leg(s). This information was provided verbally by a doctor specialised in gynaecological oncology immediately after randomisation. If they felt worried about the risk of recurrence, they could ask for a consultation. Self-referral was made easy by providing the telephone number of a designated project nurse at the department of gynaecology or, if preferred, they could contact their GP. In most cases, the women were seen within a week after contacting the department. The woman's GP was informed of the study and the woman's allocation through the discharge summary.
Women in the control group received conventional follow up care, in accordance with Danish guidelines. This was a 3-year follow-up period, consisting of scheduled visits every 4-6 months in the first 2 years and every 6 months during the third year. Because of the pragmatic study approach, variation in the frequency of follow-up visits was allowed, as each of the four centres was instructed to provide care as usual. 12 The follow-up visits included clinical and gynaecological examinations with vaginal ultrasound, supplemented with biopsies in case of suspicious findings and imaging in case of symptoms or histologically verified recurrence.
Outcomes
Data were sampled by questionnaires administered at 1, 3, 6 and 10 months of follow up and chart review. Questionnaires were primarily administered online, although a paper version was sent in case the women preferred the paper version. Sociodemographic characteristics were collected from questionnaires. From the chart review, we obtained data on primary surgery, FIGO stage, grade, histological type, comorbidities and body mass index at baseline, date of recurrence diagnosis and date of death.
This report is focused on the primary end point, FCR after 10 months of follow up, as the majority of changes in FCR are expected to occur early after treatment. Additional end points collected in the trial included quality of life, unmet needs, and post-traumatic growth after 10 months.
Finally, a long-term assessment of the above-mentioned end points and a cost-utility analysis will be conducted after 3 years of follow up.
Fear of cancer recurrence was assessed using the Fear of Cancer Recurrence Inventory (FCRI). 13 It is a multi-dimensional, 42-item questionnaire with a time frame of 1 month. It comprises seven subscales measuring different aspects associated with FCR: triggers, severity, psychological distress, reassurance-seeking, coping strategies, functioning impairments and insight (self-criticism towards FCR intensity). Each question is scored on a 5-point Likert scale from 0 'not at all' to 4 'a great deal'. A total summary score is obtained by summing all items (with item no. 13 reversed). The score ranges from 0 to 168, with a higher score indicating higher levels of FCR. A cut-off value for clinical FCR is defined as a score of ≥ 16 on the Severity subscale (range 0-36).
14 This instrument was chosen because it comprises a comprehensive assessment of FCR with a proposed cut-off score for clinically significant FCR. 15 The English version of the FCRI has demonstrated sound psychometric properties, including high internal consistency (Cronbach a 0.71-0.94), test-retest reliability (r 0.56-0.87), and construct validity. 16 Before the start of the study, the English version of the questionnaire was translated into Danish, inspired by the guidelines for crosscultural adaptation of self-report measures by Beaton et al., 17 involving a forward-backward translation approach. The translated version was pilot-tested in accordance with the guidelines of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group 18 in a population of 11 women attending follow up for endometrial cancer.
Information on primary care use was obtained from two questions regarding the number of cancer-related visits to a GP or a privately practising gynaecologist since the last questionnaire completion. Information on number of telephone contacts and examinations at the department of gynaecology was obtained by chart review. Any symptoms reported by the women at the examination were registered.
Statistical methods
The power calculation was based on pilot study data from 22 endometrial cancer patients supplemented with unpublished data derived from a study on FCR in breast cancer patients. Corresponding to these data, the expected standard deviation was set at 22. A difference in the decline of at least 10 points was considered of clinical relevance, based on experiences from scoring of quality of life measures. 19 To detect a difference of 10 in the change of total FCRI score with 80% power at the 5% level, 76 women were required in each group. To ensure that complete data were obtained for 152 women, the 10-month completion rate was estimated after 18 months of inclusion. This gave a completion rate of 72%, and so 211 women were needed for the study.
The flowchart was constructed according to the CON-SORT guidelines. Baseline characteristics of nonparticipants versus participants as well as responders versus nonresponders were compared using t-tests for continuous variables, Pearson chi-square test for categorical variables, and Mann-Whitney U-test for nonparametric variables.
Missing values on the FCRI were handled according to the scoring manual provided by the developer. 13 Questionnaires were discarded if (1) more than half of the data were missing, (2) two or more subscales were completely missing, or (3) a '0'-response pattern for the entire FCRI was used. Otherwise, missing data were imputed by the mean subscale score on a person level. Mean scores and standard deviations (SD) were calculated, and the change in total FCRI score from treatment to 10-month follow up was compared between the two trial arms using linear regression analysis adjusted for hospital and baseline score. Based on the severity subscale, the proportion of women with clinical FCR was estimated and the odds ratio for clinical FCR was estimated in a multiple logistic regression analysis adjusted for hospital and baseline.
Median number of cancer-related visits to the GP, privately practising gynaecologist, and telephone contacts and follow-up visits to the department of gynaecology within the first 10 months following treatment were estimated for both trial arms, and compared using Mann-Whitney U-tests, because the data did not meet the assumption of normal distribution.
For all analyses, a modified intention-to-treat approach was applied, as only women who completed the first and fourth questionnaires were included in the analyses. A two-sided P-value < 0.05 was considered statistically significant. Analyses were performed using STATA/IC 14.0 for Windows. The CONSORT-criteria (www.equator-network. org) were followed in the reporting of the study. The trial is registered at clinicaltrials.gov, identifier: NCT 01853865.
Patient involvement
The patient association 'Women with Reproductive Cancers' was consulted during the design phase of the trial. This resulted in changes made to the written study information as well as timing for when oral and written information was presented to eligible women.
Funding
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Results
A total of 549 women were assessed for eligibility between 1 May 2013 and 1 June 2016 and 307 women were eligible for participation. Of these, 214 women were randomised for the trial (Figure 1) . Two of these women were subsequently excluded because of high-risk disease. Baseline characteristics of participants are summarised in Table 1 . Complete data were obtained for 156/212 (74%) (Figure 1) . No evidence of a difference was found in baseline and disease characteristics between women with complete data sets and nonresponders (see Supplementary material, Table S1 ). More nonparticipants had cardiovascular disease compared with participants (73% versus 54%, P = 0.03).
No deaths were observed within the 10-month follow-up period. Disease recurrence was detected in two of the women allocated to the intervention. One 79-year-old woman contacted the department of gynaecology because of a painful palpable tumour in her left hypogastric region, whereas the other woman, 84 years old, was diagnosed at a department of general medicine as a result of general fatigue and pain in her right side, and a CT scan revealed peritoneal carcinomatosis.
At baseline, women in the control group had a mean FCR total score of 48.5 (SD 28.8). At 10 months of follow up, this score had improved by 8.0, and the majority of this improvement happened after 3 months of follow up with a reduction in overall score of 6.6 (Table 2 ). In the intervention group, the baseline score was 44.8 (SD 27.3), and this score remained more constant with an improvement of 1.4 at 10 months of follow up (Table 2 ). In the linear regression, FCR decreased significantly more in the control group with an estimated difference of À5.9 (95% CI À10.9 to À0.9; P = 0.02).
The proportion of women with clinical FCR as derived from the Severity subscale did not differ between the groups at 10 months of follow up when adjusting for baseline score and hospital (odds ratio 0.9, P = 0.89). The estimated proportions indicated that one in five women struggled with clinical FCR 10 months after their primary treatment, regardless of allocation ( Table 2 ).
All subscales improved in the control group from baseline to 10 months of follow up ( Table 2 ). The greatest improvement was seen in coping strategies, which suggested that, because of their reduced level of FCR, the women depended less on coping strategies to deal with their FCR.
Twenty-six of the women who declined participation (27% of nonparticipants) completed the baseline questionnaire. No evidence of a difference was found in the mean total FCR score when compared with participants (47.5 versus 46.6, P = 0.88).
No evidence of a difference was found between the two groups in the number of cancer-related visits to the GP (P = 0.77), privately practising gynaecologist (P = 0.31), or telephone contacts to the departments of gynaecology (P = 0.15) (Table 3) . However, women in the intervention group had significantly fewer examinations at the gynaecology departments compared with the control group (P < 0.01) ( Table 3) . Reasons for the 19 examinations in the intervention group were: vaginal bleeding or discharge (n = 11), pain in the pelvic or inguinal region (n = 4), palpable tumour (n = 1), worry (n = 1) and dropout from allocated intervention (n = 2, one woman). BMI, body mass index; RALH, robotically assisted laparoscopic hysterectomy; RARH, robotically assisted radical hysterectomy; TAH, total abdominal hysterectomy; TLH, total laparoscopic hysterectomy. Data are given as n (%) unless otherwise stated.
Discussion
Main findings
This is the first study to examine the use of patientinitiated follow up in endometrial cancer. Traditional follow up alleviated FCR more effectively than patientinitiated follow up. The intervention group had significantly fewer hospital examinations (P < 0.01) and these examinations were primarily scheduled because of symptoms, with vaginal bleeding/discharge being the most prevalent symptom.
Strengths and limitations
Study strengths include the randomised design, the fact that the required sample size was reached, and the blinding of data analysts. The pragmatic design ensured that the intervention was evaluated in real-life settings, so maximising the generalisability of the study. 12 The baseline questionnaire was completed after randomisation, as the FCRI would neither have made sense to complete nor been ethical to give out at the time of primary treatment. Responses could thus be affected by the allocation. Even so, the 1-month questionnaire was considered a credible baseline score, because it covered the experience of FCR during the past month (before randomisation).
Blinding of participants for this trial was not possible. Women who received the intervention knew that they were examined less than the control group, and we cannot rule out that this bias in part explains the constant level of FCR in the intervention group.
The regular completion of questionnaires may have served as a reminder of disease, and may have attenuated the differences between the control and intervention groups. As the women in the intervention did not receive reassurance from an examination, the questionnaire may have induced FCR in this group. Standard deviations are given in parentheses. The percentage of women with clinical FCR is based on the Severity subscale score. *Linear regression analysis adjusted for hospital and baseline score. **Odds ratio from logistics regression analysis adjusted for hospital and baseline score.
The analyses were limited to a modified intention-totreat approach. However, complete data sets were obtained from the majority of the women (73.6%), and there were no significant differences in baseline characteristics or questionnaire scores between responders and nonresponders. The participation rate was 69%, and nonparticipants could possibly represent a group that preferred hospital-based follow up. Reasons for nonparticipation were only available for five of the women, but only two of these women refused participation because of a wish for traditional follow up.
Interpretation
Only four randomised trials have compared patientinitiated follow up with traditional follow up, and these were conducted in breast and colorectal cancer survivors. [20] [21] [22] [23] No evidence of a difference was found with regard to quality of life, anxiety or depression in breast cancer, or for survival in colorectal cancer. These studies differed from the present study in two important aspects.
(1) Women in the intervention groups attended annual mammograms or conducted faecal examinations at regular intervals. (2) General anxiety was measured using the Hospital Anxiety and Depression Scale, and even though some correlation exists between anxiety, depression and FCR measures, they represent different constructs.
14 Our trial demonstrated a superior effect of traditional follow up on FCR compared with patient-initiated follow up with an estimated significant difference in total score of À5.9. Hence, we reject our hypothesis that patientinitiated follow up would reduce FCR. Women in the control group may have achieved medical reassurance at the scheduled examinations that outweighed any potential distress before the examinations. [2] [3] [4] 22 Furthermore, in the intervention group, detection of recurrence relied on the woman's ability to detect signs of recurrence. For some women, this responsibility might have led to distress, and the complete absence of a scheduled visit might have been too drastic.
No study has validated a cut-off for the minimal clinically important difference on the total FCRI score. A common approach to interpreting quality of life data is to choose a cut-off of 5-10% of the scale width. 19 To ensure sufficient power to detect a difference and considering the paucity of knowledge on minimal clinically important difference on the FCRI, we decided on a cut-off of 10 points, corresponding to 6% of the scale width. Based on the confidence interval, we are 95% confident that the true difference between the groups lies between À0.9 and À10.9. Hence, the intervention may have been clinically inferior to the control group.
In this study, the mean total score on the FCRI ranged from 40 to 48.5. In comparison, the mean total FCRI score was found to be 66.3 in survivors from lung cancer, 24 indicating an association between the actual risk of recurrence and FCR. Nonetheless, our findings revealed a large variation in scores with standard deviations between 26.5 and 29.5, suggesting that a subgroup of endometrial cancer survivors experienced high levels of fear. Future efforts should aim to identify the subgroup of women with high levels of fear to ensure appropriate follow up.
In the control group, most of the decline in total FCRI score was observed at 3 months of follow up, after which point a more constant level of FCR was reached. Hence, it is possible that a single scheduled examination after 4 months combined with a patient-initiated approach would have the same effect on FCR, although this should be examined in future trials. Other follow-up approaches, including follow up in primary care 25, 26 and nurse-led telephone follow up 27 have proven equal to traditional follow up with regard to quality of life, anxiety and time to recurrence. These two approaches are characterised by relieving the use of secondary healthcare resources, although the cancer survivors still have regular contact with healthcare personnel. Hence, it is likely that these interventions would contain an element of medical reassurance that could be lacking from patient-initiated follow up. Patient-initiated follow up has the potential to reduce diagnostic delay by encouraging patients to respond to symptoms immediately, 9 and the patients do not need a referral to specialised care from the GP. 20 These benefits rely on the patient's ability to monitor and react to symptoms without being distressed and require excessive testing by their healthcare provider. Our findings clearly demonstrate that patient-initiated follow up is feasible in endometrial cancer. Use of primary care and telephone contacts did not differ between the two groups, whereas the intervention group required significantly fewer examinations at the gynaecology departments. It is unknown whether some women in the intervention group experienced symptoms to which they did not react, although we have no reason to suspect this. In a previous study, 8 we concluded that women diagnosed with recurrence at an interval visit because of symptoms were more likely to have high-risk disease and a higher educational level. Other studies have identified risk factors for delayed presentation of symptoms, 28, 29 including older age, lower socio-economic status, atypical symptom types, comorbidity and lack of symptom awareness. These potential delayers should be taken into account when instructing women on alarm symptoms, to ensure that they are sufficiently prepared for self-referral.
Conclusion
Traditional follow up reduced FCR significantly more than patient-initiated follow up, though the estimated difference was small. The population of cancer survivors is growing, which has resulted in an increasing strain on healthcare resources. Women treated for stage I low-to intermediate-risk endometrial cancer have a low risk of recurrence, and patient-initiated follow up represents a feasible alternative, with the potential of reducing the use of health care. The decision of whether the benefits of patient-initiated follow up outweigh the harms will be supported by future long-term analyses on quality of life and cost-utility.
Disclosure of interests
None declared. Completed disclosure of interests form available to view online as supporting information.
Contribution to authorship
MMJ was involved in all phases of the literature search, design, data collection and cleaning, design of tables and figures, interpretation and writing of the manuscript. PTJ, DGH and OM acted as supervisors and were therefore actively involved in the study design, data collection and interpretation, and writing of the journal manuscript. RDC performed the sample size calculations and the statistical analyses and took part in writing of the journal manuscript with specific emphasis on sections regarding statistics and results.
Details of ethics approval
The study was conducted in accordance with the Declaration of Helsinki and was approved by the Regional Scientific Ethical Committees for Southern Denmark (S-20120223, approval date: 21 March 2013) and the Danish Data Protection Agency (12/25796).
Funding
The research for this article was financially supported by the Danish Cancer Society, (grant no. R94-A5679 Rp7423), the National Research Centre of Cancer Rehabilitation, University of Southern Denmark, the Region of Southern Denmark (grant no. 13/6697), and Odense University Hospital (grant no. 12/26914). The funders of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report.
